Bicara Therapeutics (NASDAQ:BCAX) Upgraded by Wedbush to “Strong-Buy” Rating

Wedbush upgraded shares of Bicara Therapeutics (NASDAQ:BCAX) to a strong-buy rating in a report issued on Wednesday,Zacks.com reports.

Several other research analysts also recently issued reports on BCAX. Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $47.00 target price on the stock. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price on the stock. HC Wainwright upped their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. TD Cowen assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. Finally, Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $41.20.

Bicara Therapeutics Stock Performance

NASDAQ:BCAX opened at $12.60 on Wednesday. Bicara Therapeutics has a one year low of $11.10 and a one year high of $28.09. The business’s 50-day simple moving average is $16.00.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Research analysts anticipate that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. purchased a new stake in shares of Bicara Therapeutics in the fourth quarter worth $2,731,000. Bank of New York Mellon Corp purchased a new stake in shares of Bicara Therapeutics in the fourth quarter worth $701,000. Rhumbline Advisers purchased a new stake in shares of Bicara Therapeutics in the fourth quarter worth $331,000. Spire Wealth Management purchased a new stake in shares of Bicara Therapeutics in the fourth quarter worth $31,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Bicara Therapeutics in the fourth quarter worth $147,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.